OncoVista Innovative Therapies Inc  

(Public, OTCMKTS:OVIT)   Watch this stock  
Find more results for OTC:OVIT
-0.020 (-2.56%)
Delayed:   12:34PM EDT
OTCMKTS data delayed by 15 mins - Disclaimer
Currency in USD
Range 0.75 - 0.78
52 week 0.01 - 1.16
Open 0.78
Vol / Avg. 9,500.00/54,764.00
Mkt cap 16.73M
P/E     -
Div/yield     -
EPS -0.12
Shares 22.01M
Beta -0.79
Inst. own 9%

Key stats and ratios

Q1 (Mar '15) 2014
Net profit margin - -
Operating margin - -
EBITD margin - -
Return on average assets -3247.77% -4675.90%
Return on average equity - -
Employees 3 -
CDP Score - -


14785 Omicron Dr Ste 104
SAN ANTONIO, TX 78245-3222
United States - Map
+1-210-6776000 (Phone)


Oncovista Innovative Therapies, Inc. (OVIT) is a biopharmaceutical company developing targeted anticancer therapies by utilizing tumor-associated biomarkers. OVIT’s product pipeline is comprised of advanced (Phase II) and early (Phase I) clinical-stage compounds, late preclinical drug candidates and early preclinical leads. The Company’s lead products include Cordycepin (OVI-123) and L-Nucleoside Conjugates (OVI-117). Cordycepin (OVI-123), which contains 3’-deoxyadenosine, is indicated for the treatment of TdT-Positive Refractory Leukemias. L-Nucleoside Conjugates (OVI-117) is a thymidylate synthase (TS) inhibitor. OVI-117 is indicated for the treatment of colon cancer. OVI-117 has shown tumor growth inhibitory activity in human colon, breast and prostate tumors growing in animal models.

Officers and directors

Alexander L. Weis Ph.D. Chairman of the Board, President, Chief Executive Officer, Chief Financial Officer, Secretary
Age: 65
William J. Brock Independent Director
Age: 65
Alexander Ruckdaeschel Independent Director
Age: 43